Oncology

There is much to be learned and progress to be made in all these efforts toward the optimization of tolerability, safety, and efficacy of oncologic therapies.

Investigators identified a specific subgroup of patients with mantle cell lymphoma who were at higher risk by defining a combination of MIPI, Ki-67, and p53/TP53 alternations.

The trial was recommended to continue to analyze event-free survival rates, but current results are encouraging for treating estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Patient retraces her treatment journey from diagnosis through treatment for glioblastoma.

It was previously undetermined whether the combination of IVIG and ICI would lead to patient complications or reduced efficacy of the cancer treatment, but 2 successful case reports dispel that belief.

Risks of genitourinary and gastrointestinal toxicity were reduced significantly, but longer follow-up is necessary to examine potential future issues.

A panel of experts discuss the state of biosimilars today and the importance of standardizing knowledge of the field.

Rates of hospitalizations and mortality from COVID-19 were more than 4 times lower in 2022 compared to 2021, as the virus become less severe with new mutations, a recent study found.

Pembrolizumab is already indicated to treat patients with unresectable or metastatic melanoma, along with stage 2B-3 melanoma after resection in adults and pediatric patients.

The updated version of the Oncology Care Model (OCM) incentivizes value-based care over volume, but some wonder if it is enough.

Co-developers Incyte and Syndax will submit a biologics license application to the FDA at the end of 2023 based on the results of a phase 2 trial among adult and pediatric patients with chronic graft-versus-host disease.

Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.

Data suggest the therapy can induce prolonged clinical benefit, even after treatment discontinuation.

Building on promising prior research, ERβ was found to prevent aggressive forms of breast cancer from metastasizing.

Previous research has determined the role of dysregulation in the evolution of cancers but lacked investigation of the ability of these mutations to predict different forms and aggressiveness of cancer.

Amivantamab-vmjw in combination with chemotherapy could assist patients diagnosed with non–small cell lung cancer when chemotherapy alone did not show benefit.

There are currently no effective treatments for CIPN prevention.

Quitting treatment may significantly improve severe hypertension in patients with hepatocellular carcinoma.

These data support a paradigm shift in the treatment of locally advanced rectal cancer.

FRα expression is limited on normal cells, but upregulated in ovarian cancer cells.

Due to the assessment of computerized tomography with criteria from 1999, the role of radiotherapy in patients with diffuse large B-cell lymphoma with bulky or extranodal disease remains undefined.

The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.

Neither of the 2 current standards of care offers patients a cure.

With approximately 2 years of additional follow-up, lenvatinib plus pembrolizumab maintained robust effectiveness for nearly every patient.

Mounting concerns about availability of cancer drugs raise questions about the current supply

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Chemotherapy may increase inflammatory biomarkers that can impact the diversity of the gut microbiome, leading to serious anthropomorphic changes among women treated for early-stage breast cancer.

A panel at the Advanced Topics for Oncology Pharmacy Professionals Summit discusses strategies to address patients’ fears and distrust of the medical and scientific community.